392 NGOs call on WHO to operationalise fair and equitable benefit sharing of Covid-19 medical products

The NGOs are referring to the benefits arising from the sharing of SARS-CoV-2 digital sequence information and samples as recognised by the Convention on Biological Diversity (which has 196 Parties) and its Nagoya Protocol (which has 123 Parties).

Specifically, they have asked WHO to urgently:

1. Secure binding commitments from biopharmaceutical companies and other manufacturers for the rapid supply of existing and future medical products, especially diagnostics, therapeutics and vaccines to developing and least developed countries at an affordable price.
2. Organise open platforms for the widespread and unconditional sharing of technology and knowledge including technical specifications, designs, blueprints and any other know-how to scale-up local/regional manufacturing of medical products required for COVID-19 response including diagnostics, therapeutics and vaccines; and towards that end to secure binding commitments from biopharmaceutical companies and other medical product manufacturers.
3. Proactively coordinate and direct COVID-19 R&D by setting up an open innovation platform for the rapid public sharing of all research outcomes, knowledge gaps and problem solving, and towards that end secure binding commitments from entities and individuals engaged in the R&D.
4. Ensure that intellectual property rights do not affect or hinder efforts to curb the Covid outbreak.

Download here (Third World Network, letter dated April 24, 2020)